Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid in Pregnant Women with Mild-to-Moderate COVID-19
NCT05386472Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Pfizer. Primary endpoints: Apparent Oral Clearance at Day 5, Apparent Volume of Distribution at Day 5 and 6 more. Started Jun 2022; status: terminated.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05386472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386472.